文献速递外周动脉疾病

斑块旋切联合球囊扩张与单纯球囊扩张治疗孤立性胫动脉病变的CLTI比较

Atherectomy with Angioplasty versus Angioplasty Alone for Critical Limb-Threatening Ischemia with Isolated Tibial Disease.
PubMed 文献 · Ann Vasc Surg · 2026-04-05

基于TriNetX数据库的回顾性队列研究,比较CLTI合并孤立性胫动脉病变患者接受胫动脉斑块旋切联合球囊扩张与单纯球囊扩张的结局。倾向评分匹配后每组749例,随访5年。旋切组5年小截肢率(23.4% vs 30.0%)和大截肢率(14.6% vs 18.4%)显著更低,死亡率和再干预率相当。

要点

  • 旋切联合球囊扩张组5年小截肢率显著低于单纯球囊扩张组(23.4% vs 30.0%)。
  • 旋切组5年大截肢率也显著更低(14.6% vs 18.4%,OR 0.75)。
  • 两组3个月及5年死亡率和再干预率无显著差异。

核心结论

  • 对于CLTI合并孤立性胫动脉病变首次血运重建患者,斑块旋切可能较单纯球囊扩张降低截肢风险。

研究设计与样本

  • 旋切辅助血管成形术组752例,单纯球囊扩张组3195例,倾向评分1:1匹配后每组749例。
  • 匹配后男性占72.1%,白人占63.7%,平均年龄66.5±12.3岁。
  • 平均随访时间旋切组687天,球囊扩张组744天。

主要发现

  • 3个月时两组死亡率(OR 1.13,95%CI 0.73-1.74)、大截肢率(OR 1.08,95%CI 0.77-1.51)和再干预率(OR 1.06,95%CI 0.81-1.40)无显著差异。
  • 3个月时旋切组小截肢率显著更低(OR 0.74,95%CI 0.57-0.96)。
  • 5年时旋切组小截肢率显著更低(23.4% vs 30.0%,OR 0.71,95%CI 0.56-0.89)。
  • 5年时旋切组大截肢率显著更低(14.6% vs 18.4%,OR 0.75,95%CI 0.57-0.99)。
  • 3个月、12个月和5年大截肢风险比接近1,5年HR为0.816。

临床怎么用

  • 对于CLTI合并孤立性胫动脉病变的首次血运重建,可考虑斑块旋切联合球囊扩张以降低远期截肢风险。
  • 需个体化评估,结合病变特征和患者合并症选择血运重建策略。

局限性

  • 回顾性队列设计存在残余混杂可能。
  • 原文未报告具体局限性的详细说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Critical limb-threatening ischemia (CLTI) causes significant morbidity and mortality worldwide. Although simple balloon angioplasty has been around for decades, the use of atherectomy devices for CLTI treatment has expanded exponentially in recent years. There remains a gap in research on the comparative outcomes of adjunct atherectomy versus stand-alone angioplasty in patients with critical limb ischemia, particularly for patients with isolated tibial disease. METHODS: Using TriNetX Data Network, a global federated database of over 250 million patients, we conducted a retrospective cohort study of CLTI patients who underwent tibial atherectomy versus balloon angioplasty alone, up to July 2024. Patients younger than 18 years or with a history of prior or concomitant vascular intervention, including open and endovascular procedures, were excluded. Eligible patients were 1:1 propensity score-matched for preoperative covariates, including demographics and comorbidities. Three-month, 12-month, and 5-year outcomes of mortality, major and minor amputations, and reintervention were calculated and compared between the 2 cohorts using odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: This study identified 752 patients who underwent atherectomy-assisted angioplasty and 3,195 who underwent angioplasty alone. A total of 749 patients in each cohort were matched to compare outcomes spanning 5 years. In total, 72.1% were male, 63.7% White, and the mean age was 66.5 ± 12.3 (Table 1). The mean follow-up period was 687 days for the atherectomy group and 744 days for the angioplasty group. Three-month outcomes resulted in comparable OR for mortality (OR [95% CI] = 1.13 [0.73-1.74]), major amputation (OR [95% CI] = 1.08 [0.77-1.51]), and reintervention (OR [95% CI] = 1.06 [0.81-1.40]). However, atherectomy was associated with significantly fewer minor amputations (OR [95% CI] = 0.74 [0.57-0.96]). The same trend continued out to 5 years, with comparable mortality and reintervention rates and significantly fewer minor amputations (23.4% vs. 30.0%, OR [95% CI] = 0.71 [0.56-0.89]) in the atherectomy group. Notably, major amputation was also significantly lower in the atherectomy group at 5 years compared to the balloon angioplasty group (14.6% vs. 18.4%, OR [95% CI] = 0.75 [0.57-0.99]). HRs for major amputation at 3 months, 12 months, and 5 years were close to 1, with the 5-year HR at 0.816. CONCLUSION: This study suggests a potential clinical advantage of atherectomy for first-time revascularization in patients with critical limb ischemia and isolated tibial disease. The reductions in adverse outcomes suggest atherectomy offers long-term clinical benefits over angioplasty alone, warranting further investigation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ebirim EC, Ramachandran S, Tsukagoshi J, et al. Atherectomy with Angioplasty versus Angioplasty Alone for Critical Limb-Threatening Ischemia with Isolated Tibial Disease. Ann Vasc Surg. 2026. PMID: 41941893. doi:10.1016/j.avsg.2026.03.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。